Crystalys Therapeutics is a biopharmaceutical company dedicated to advancing global Phase 3 clinical studies of dotinurad, a next-generation URAT1 inhibitor for the treatment of gout. The company leverages a world-class team with extensive experience in gout drug development and regulatory success, aiming to deliver a treatment with potential best-in-class safety and efficacy. Dotinurad has already demonstrated robust efficacy and a well-defined safety profile in multiple clinical studies across Asia, leading to its approval in Japan, China, Philippines, and Thailand.
Key Executives
Crystalys Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Crystalys Therapeutics had 23 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Crystalys Therapeutics had 3,375 followers as of November 2, 2026. The number of followers increased by 24 (0.72%) week-over-week.
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 22, 2026 | Series B | $130.00M | ― |
| Oct 08, 2025 | Series A | $205.00M | ― |
| Investor Name | Funding Round |
|---|---|
| Frazier Life Sciences | Series B |
| Wellington Management | Series B |
| HBM Healthcare Investments | Series B |
| Soleus Capital | Series B |
| Cormorant Asset Management | Series B |
| Trails Edge Capital Partners | Series B |
| Pivotal bioVenture Partners | Series B |
| KCap Biotechnology Fund | Series B |
A snapshot of private companies similar to Crystalys Therapeutics, helping you discover and navigate related company profiles.

